InvVax

<p>Physicians are often frustrated by the seasonal flu vaccine&#39;s poor effectiveness every year. With our product they can be confident that they are administering something that not only will work, but will last at least 4-5 years, and will not be rendered ineffective because of the virus&#39;s natural mutation. They can be confident that elderly people and the very young, in short, those who need it most, can be protected from not just illness as a whole but severe illness, hospitalization, and death. And finally, they can be assured that in the event of a global pandemic, those whom they give the vaccine are fully protected.</p>

<p>Between 140,000 and 710,000 hospitalizations for flu occur every year in the US (https://www.cdc.gov/flu/about/disease/burden.htm). Reducing this greatly will lift a tremendous burden from hospitals nationwide. Far worse is the real -- and as many experts believe, inevitable -- pandemic, in which cases hospitals would simply be overwhelmed by this one disease alone. Our product will effectively protect everyone who receives it from this situation, since it cross-protects against any strain of flu, bird flu and swine flu included.</p>

<p>Currently about seven or eight Big Pharma have&nbsp;a seasonal flu vaccine on the market, with little difference between them (and as stated above, poor effectiveness across the board).&nbsp;Whoever acquires our brand will undoubtedly shoot to the top, and most likely will take over the market. As such, we expect much competition among Big Pharma to acquire us at some point in the clinical trials process.</p>